摘要
目的探讨血清神经特异性烯醇化酶(NSE)、胃泌素释放肽前体(proGRP)在小细胞肺癌患者诊断和复发的价值。方法选择50例肺部良性病变患者,89例非小细胞肺癌患者,77例小细胞肺癌患者。测定所有患者血清NSE和proGRP。结果非小细胞肺癌与肺部良性病变组比较血清NSE差异有统计学意义(P<0.05),血清proGRP差异无统计学意义(P>0.05);小细胞肺癌与肺部良性病变、非小细胞肺癌血清proGRP、NSE均有明显差异(P<0.01)。对于小细胞肺癌复发血清proGRP准确率为72.3%,NSE准确率为57.4%,联合检测准确率为87.2%,联合检测对复发判断更准确(P<0.05)。结论血清NSE和proGRP检测对于小细胞肺癌诊断和复发有重要意义。
Objective To study the value of serum （neuron specific enolase）NSE and （progastrin-releasing peptide） proGRP on diagnosis and relapse in patients with small cell lung cancer.Methods 50 patients with benign pulmonary disease,89 patients with non-small cell lung cancer,77 patients with small cell lung cancer were enrolled.Serum NSE and proGRP were detected.Results There was a significant difference between patients with benign pulmonary disease and non-small cell lung cancer about NSE（P0.05）. There wasnt a significant difference between patients with benign pulmonary disease and non-small cell lung cancer about proGRP（P0.05）.Serum NSE and proGRP in patients with small cell lung cancer were higher than these in patients with non-small cell lung cancer and benign pulmonary disease（P0.01）. Compared with separate NSE and proGRP, accuracy through serum NSE and proGRP was higher（P0.05）.Conclusion Serum NSE and proGRP can play a importment parts about diagnosis and relapse in patients with small cell lung cancer.
出处
《中国实用医药》
2013年第16期4-5,共2页
China Practical Medicine
